Showing results (21-30 of 30) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Proceedings of the National Academy of Sciences of the United States of America|April 25, 2018
Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancerJohn K Lee, Nathanael J Bangayan, Timothy Chai, et al.Science (New York, N.Y.)|October 6, 2018
Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineageJung Wook Park, John K Lee, Katherine M Sheu, et al.Cancer Cell|April 7, 2016
N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial CellsJohn K Lee, John W Phillips, Bryan A Smith, et al.Journal of Cardiac Failure|August 24, 2019
Discordance Between Clinical Assessment and Invasive Hemodynamics in Patients With Advanced Heart FailureNikhil Narang, Ben Chung, Ann Nguyen, et al.Journal of Cardiac Failure|May 28, 2021
Aortic Pulsatility Index: A Novel Hemodynamic Variable for Evaluation of Decompensated Heart FailureMark N Belkin, Sara Kalantari, Anthony J Kanelidis, et al.Proceedings of the National Academy of Sciences of the United States of America|December 25, 2019
A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypesLiang Wang, Bryan A Smith, Nikolas G Balanis, et al.Cell|August 9, 2016
Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate CancerJustin M Drake, Evan O Paull, Nicholas A Graham, et al.Artificial Organs|December 27, 2022
Postoperative tolvaptan use in left ventricular assist device patients: The TOLVAD randomized pilot studyMark N Belkin, Teruhiko Imamura, Daniel Rodgers, et al.Proceedings of the National Academy of Sciences of the United States of America|October 4, 2016
Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancerTanya Stoyanova, Mireille Riedinger, Shu Lin, et al.Science Translational Medicine|December 6, 2019
Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancerYanjing Li, Yiping He, William Butler, et al.Pageof 3